Harmony Biosciences
HRMY
211 hedge funds and large institutions have $1.83B invested in Harmony Biosciences in 2023 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 86 increasing their positions, 65 reducing their positions, and 40 closing their positions.
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
32% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 65
9% more capital invested
Capital invested by funds: $1.68B → $1.83B (+$153M)
0.62% more ownership
Funds ownership: 86.07% → 86.69% (+0.62%)
3% less funds holding
Funds holding: 217 → 211 (-6)
15% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 40
52% less call options, than puts
Call options by funds: $4.37M | Put options by funds: $9.12M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$27.3M |
| 2 |
BlackRock
New York
|
+$27.3M |
| 3 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$15.1M |
| 4 |
Man Group
London,
United Kingdom
|
+$11M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$9.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$27.9M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$19.5M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$9.67M |
| 4 |
Corient Private Wealth
Miami,
Florida
|
-$9.25M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.42M |
HRMY Hedge Fund Activity: Q2 2023 in Review
211 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q2 2023, worth a combined $1.83B — up 9.2% from $1.68B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of HRMY and 34 opened new positions — a net loss of 6 holders — while 65 trimmed existing stakes and 86 added.
The largest buyer was Perceptive Advisors, adding an estimated $27.3M. The largest seller was Invesco, cutting an estimated $27.9M.
- 211 institutional investors held Harmony Biosciences (HRMY) as of Q2 2023, down from 217 in Q1 2023.
- Funds reported $1.83B of Harmony Biosciences stock for Q2 2023, up 9.2% quarter-over-quarter.
- 34 funds opened new Harmony Biosciences positions in Q2 2023 and 40 closed out, a net change of -6 holders.
- The largest Harmony Biosciences buyer in Q2 2023 was Perceptive Advisors, an estimated $27.3M added.
- The largest Harmony Biosciences seller in Q2 2023 was Invesco, an estimated $27.9M sold.
Based on aggregated 13F filings for Q2 2023.